SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (7237)8/26/2017 11:45:26 AM
From: Jibacoa  Read Replies (2) | Respond to of 7424
 
O.T.
It seems that its deal with NVS is what caused the spike on XOMA yesterday:
finance.yahoo.com

NVS has closed its June 22 UG and with the EC approval of Kisqali (ribociclib). for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer as initial endocrine-based therapy,
It also seems that NVS' R/R is now favorable and it may resume its previous up-trend. <g>
https://stockcharts.com/c-sc/sc?s=NVS&p=D&b=5&g=0&i=t96771839772&r=1503761609668

Bernard